This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stuart L. Nightingale, MD; Peter H. Rheinstein, MD, JD, MS; James C. Morrison
Food and Drug Administration Rockville, Md

JAMA. 1989;261(17):2499-2500.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

An article entitled "Increased Seizure Frequency With Generic Primidone"1 contained specific observations of a patient, including blood levels, and was of particular concern to the Food and Drug Administration because it alleged the therapeutic failure of a generic primidone product that had been evaluated by the administration as therapeutically equivalent to the trade name product Mysoline.

This is to report that the Food and Drug Adminstration's Therapeutic Inequivalence Action Coordinating Committee initiated an investigation on publication of the article. The authors were contacted, investigators looked at hospital records, and samples of the batch of the drug product in question were analyzed. Samples of the product showed that it met all US Pharmacopeia and Food and Drug Administration standards. An inspection of the manufacturer revealed no manufacturing problems. The failure actually occurred in October 1985, nearly 2 years before publication of the article. Three months after switching . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?